Fayon M, Martinez-Cingolani C, Abecassis A, Roders N, Nelson E, Choisy C, Talbot A, Bensussan A, Fermand J-P, Arnulf B, Bories J-C. Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica 2021; 106(4):1193-1197; https://doi.org/10.3324/haematol.2019.242453.